Theriva Biologics Receives Notice Of Allowance For US Patent Application Titled "Beta-Lactamase Formulations & Uses Thereof" For Treating C. Difficile Disease And Other Antibiotic-Induced GI Tract Adverse Effects
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics has received a Notice of Allowance for a US patent application concerning beta-lactamase formulations aimed at treating C. difficile disease and other antibiotic-induced GI tract adverse effects.
August 28, 2024 | 7:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theriva Biologics has been granted a Notice of Allowance for a US patent application on beta-lactamase formulations, which could enhance their product offerings for treating C. difficile and other GI tract issues.
The Notice of Allowance for a patent application is a positive development for Theriva Biologics, as it could lead to new product offerings and enhance their market position in treating C. difficile and other GI tract issues. This news is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100